|
RRAS2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
4.75397499144492E-13 |
| Normal-vs-Stage3 |
1.85407245112401E-14 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
2.529600E-01 |
| Stage1-vs-Stage3 |
3.994000E-01 |
| Stage1-vs-Stage4 |
4.236100E-04 |
| Stage2-vs-Stage3 |
6.727600E-01 |
| Stage2-vs-Stage4 |
1.152810E-01 |
| Stage3-vs-Stage4 |
2.392100E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
4.90220000148867E-08 |
| Normal-vs-Asian |
3.90321108767466E-12 |
| Caucasian-vs-AfricanAmerican |
8.888400E-01 |
| Caucasian-vs-Asian |
7.067800E-01 |
| AfricanAmerican-vs-Asian |
9.084400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.44089209850063E-16 |
| Normal-vs-Female |
1.6242562850266E-12 |
| Male-vs-Female |
5.001400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.63025148935958E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
1.372350E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.917900E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.152050E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.973400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.047200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.504200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.683800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.757800E-01 |
| Classical-VS-Follicular |
1.445570E-01 |
| Classical-VS-Other |
4.793400E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
8.331600E-01 |
| Tall-VS-Other |
3.522400E-01 |
| Tall-VS-Normal |
2.51190002131807E-09 |
| Follicular-VS-Other |
2.907600E-01 |
| Follicular-VS-Normal |
1.64046554118613E-12 |
| Other-VS-Normal |
1.132300E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
3.64153152077051E-13 |
| N0-vs-N1 |
5.113000E-01 |
|
|
